JP Morgan Upgrades Afya to Overweight from Neutral
On October 7, 2026, JP Morgan upgraded their outlook for Afya (NASDAQGS:AFYA) (DB:1AY) from Neutral to Overweight. This rating action follows a prior action on June 22, 2026, when JP Morgan maintained its rating of Neutral.
The pre-action close for the stock was $13.92 on October 6, 2026. The latest close was also $13.92 on October 6, 2026, which represents a price change of +17.72% over one week from a baseline close of $11.82 on September 29, 2026. The stock also recorded a one-month price change of -5.21% from a baseline close of $14.68 on September 4, 2026.
Separate from the individual rating action, the current consensus target mean for the stock was $17.17 as of October 2, 2026, representing an implied change of +23.39%. The current consensus target median was $16.83 as of October 2, 2026. This represents a consensus target revision of +2.02% from the prior consensus target mean of $16.83 as of September 16, 2026.
The current recommendation period as of September 1, 2026, shows a total of 13 recommendations, consisting of 1 buy, 7 hold, 3 sell, and 2 strong sell recommendations. This distribution represents 7.7% positive, 53.8% hold, and 38.5% negative recommendations.
On its latest earnings date of August 13, 2026, Afya reported an actual EPS of 2.3, compared to an estimated EPS of 2.1896, which is an EPS surprise of +5.04%. The company's actual revenue was $972,097,000.00, while the estimated revenue was $1,007,154,120.00.
Afya Limited is a medical education group based in Brazil, specializing in training healthcare professionals primarily through its medical education services. The company operates a comprehensive network of undergraduate and graduate healthcare courses, from medical school degrees to continuing medical education programs. To achieve its objectives, Afya employs a strategy that includes the acquisition and development of new schools, expansion of its course offerings, and investment in digital platforms to support both on-campus and remote learning.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 7, 2026 | JP Morgan | Neutral | Overweight | upgrade |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.